Summary
The binding of docetaxel to human plasma proteins was studied by ultrafiltration at 37°C and pH 7.4. Docetaxel was extensively (> 98%) plasma protein bound. At clinically relevant concentrations (1–5 μg/ml), the plasma binding was concentration-independent. Lipoproteins, alpha1-acid glycoprotein and albumin were the main carriers of docetaxel in plasma, and owing to the high interindividual variability of alpha1-acid glycoprotein plasma concentration, particularly in cancer, it was concluded that alpha1-acid glycoprotein should be the main determinant of docetaxel plasma binding variability. Drugs potentially coadministered with docetaxel (cisplatin, dexamethasone, doxorubicin, etoposide, vinblastine) did not modify the plasma binding of docetaxel. In blood, docetaxel was found to be mainly located in the plasma compartment (less than 15% associated to erythrocytes).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN: The taxoids: paclitaxel (Taxol®) and docetaxel (Taxotere®). Cancer Treatment Rev 19:351–386, 1993
Bruno R, Sanderink GJ: Pharmacokinetics and metabolism of Taxotere (Docetaxel). Cancer Surveys 17:305–313, 1993
Bruno R, Hille D, Thomas L, Riva A, Sheiner L: Population pharmacokinetic/pharmacodynamic (PK/PD) studies of docetaxel (Taxotere®) in phase II studies. Proc Am Soc Clin Oncol 14:457, 1995
Routledge PA: The plasma protein binding of basic drugs. Br J Clin Pharmacol 22:499–506, 1986
Tillement JP, Houin G, Zini R, Urien S, Albengres E, Barré J, Lecomte M, D'Ahis P, Sébille B: The binding of drugs to biological macromolecules in plasma. Recent advances and therapeutic significance. Adv Drug Res 13:59–94, 1984
Havel RJ, Eder HA, Bragton JM: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34:1345–1354, 1955
Urien S, Riant P, Renouard A, Coulomb A, Rocher I, Tillement JP: Binding of indapamide to serum proteins and erythrocytes. Biochem Pharmacol 37:2963–2966, 1988
Urien S: MicroPharm. A software designed to analyse pharmacological data from kinetic, binding and tissue extraction experiments. Bull Cancer 78:654, 1991
Blain PG, Mucklow JC, Rawlins MD, Roberts DF, Routledge PA, Shand DG: Determinants of plasma alpha1-acid glycoprotein concentrations in health. Br J Clin Pharmacol 20:500–502, 1985
Abramson FP: Methadone plasma protein binding: Alterations in cancer and displacement from alpha1-acid glycoprotein. Clin Pharmacol Ther 32:652–658, 1982
Urien S, Albengres E, Pinquier JL, Tillement JP: Role of alpha1-acid glycoprotein, albumin and nonesterified fatty acids in serum binding of apazone and warfarin. Clin Pharmacol Ther 39:683–689, 1986
Kumar GN, Walle UK, Bhalla KN, Walle T: Binding of taxol to human plasma, albumin and alpha1-acid glycoprotein. Res Commun Chem Pathol Pharmacol 80:337–344, 1993
Belpaire FM, Bogaert MG: Pharmacokinetic and pharmacodynamic consequences of altered binding of drugs to alpha1-acid glycoprotein. In: Baumann P, Eap C, Müller WE, Tillement JP (eds) Alpha1-acid Glycoprotein. Genetics, Biochemistry, Physiological Functions and Pharmacology. Alan R. Liss, Inc., New York, 1989, pp 337–350
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Urien, S., Barré, J., Morin, C. et al. Docetaxel serum protein binding with high affinity to alpha1-acid glycoprotein. Invest New Drugs 14, 147–151 (1996). https://doi.org/10.1007/BF00210785
Issue Date:
DOI: https://doi.org/10.1007/BF00210785